$BRIBY News
Last published 3y ago
- 3y agoBRIBYVBIVBrii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis BPR NewswireBRII-179 (VBI-2601) as an add-on therapy to standard of care PEG-IFNα increases HBsAg loss rate at the end of treatment and 12 weeks follow up Significantly increased HBsAg seroconversion rate is strongly associated with
- 3y agoBRIBYVBIVVIRBrii Biosciences Provides Corporate Updates and Reports 2023 Interim ResultsPR NewswireFirst patient dosed in a PEG-IFN-α controlled BRII-835 + PEG-IFN-α combination Phase 2 study for HBV functional cure First of several studies to investigate the potential of BRII-179 in enriching patients with strong
- 3y agoBRIBYVBIVBrii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to CurePR NewswireExtension of BRII-179 license from VBI Vaccines to global rights bolsters Brii Bio's position to achieve best-in-class HBV functional cure in broad patient populations Company also acquires exclusive rights to
- 3y agoANTXBRIBYVBIVVIRBrii Biosciences Provides Latest Clinical Development and Corporate UpdatesPR NewswireCompany extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from BRII-835 + PEG-IFN-α study have demonstrated that robust
- 3y agoBRIBYBrii Biosciences Announces Entry into Definitive Agreements from Sale of its Equity Interest in Qpex Biopharma and Acquiring Exclusive Global Rights for BRII-693PR NewswireCompany acquires exclusive global rights of the novel lipopeptide BRII-693 for the difficult to treat MDR/XDR gram-negative bacterial infections
- 3y agoBRIBYVBIVVIRBrii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023PR NewswireLate-breaking data from BRII-835 + PEG-IFN-a study demonstrate anti-HBs titers at the end of treatment were associated with sustained HBsAg loss 24 weeks after the end of treatment New data show more robust and
- 3y agoBRIBYBrii Biosciences Announces First Subject Dosed in Phase 1 Clinical Trial of BRII-297, Long-Acting Injectable for the Treatment of Anxiety and Depressive DisordersPR NewswireBRII-297, a first-of-its-kind treatment option for anxiety and depressive disorders, has the potential to enable greater therapeutic adherence and convenience for patients DURHAM, N.C. and BEIJING, May 31, 2023
- 3y agoBRIBYBrii Bio Publishes 2022 Environmental, Social and Governance ReportPR NewswireBrii Bio receives an "A" grade in the latest MSCI ESG Rating DURHAM, N.C. and BEIJING, April 27, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company," stock code: 2137.HK), a
- 3y agoANTXBRIBYVBIVVIRBrii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial ResultsPR NewswireCompany maintains priority focus on clinical programs to develop a novel functional cure for hepatitis B viral (HBV) infection and a potential first-of-its-kind treatment for postpartum depression (PPD) and major
- 3y agoBRIBYBrii Biosciences Provides Update on Strategic Clinical Development ProgressPR NewswireTopline Phase 2 data from multiple hepatitis B viral (HBV) infection functional cure combination studies expected in the first half of 2023 Initiation of Phase 2 postpartum depression (PPD) study planned for early 2023
- 4y agoBRIBYBrii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022PR NewswireFindings from two Phase 1 studies show both BRII-732 and BRII-778 are safe and well-toleratedResults indicate potential for oral once-weekly, long-acting combination therapy for HIV infection, supporting continued
- 4y agoBRIBYBrii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum DepressionPR NewswireData demonstrated that a single administration of BRII-296 at 600 mg delivered a favorable pharmacokinetic profile and is safe and well-tolerated in healthy subjects Findings suggest BRII-296 has potential to provide a safe and effective, one-time inje
- 4y agoBRIBYBrii Biosciences Appoints Taiyin Yang to Board of Directors, Strengthening Product Quality Oversight to Support Company MomentumPR NewswireAddition increases diversity of Board governance and supports further independent expertise DURHAM, N.C. and BEIJING, Aug. 31, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a multi-national company
- 4y agoBRIBYVIRBrii Biosciences Provides Corporate Update and Reports 2022 Interim ResultsPR NewswireAdditions to executive team strengthen global leadership and position Company for strategic long-term growth First-ever product launch of long-acting amubarvimab/romlusevimab combination therapy for COVID-19 in China advances Brii Bio from clinical de
- 4y agoBRIBYBrii Biosciences Appoints Eleanor de Groot as Chief Technology Officer and Aleksandar Skuban as Central Nervous System Diseases Therapy Area HeadPR NewswireBuilding a leadership team with global and local experience and expertise to enable rapid execution across Company's broad therapeutic strategy DURHAM, N.C. and BEIJING, Aug. 22, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Compa
- 4y agoBRIBYBrii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Live Omicron Virus BA.4/5 and BA.2.12.1 SubvariantsPR NewswireIndependent lab results demonstrate that the combination therapy retains neutralizing activity against currently dominant COVID-19 strains, as previously demonstrated with all variants of concern to date The amubarvimab/romlusevimab combination is comm
- 4y agoBRIBYBrii Bio Announces Strategic Partnership with China Resources Pharmaceutical Commercial Group to Advance the Commercialization of Long-acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in ChinaPR NewswireThe partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China The amubarvimab/romlusevimab combination is the first locally-discovered and approved SARS-CoV-2 target-specifi
- 4y agoBRIBYBrii Biosciences Appoints Dr. Susannah Cantrell as Chief Business OfficerPR NewswireStrategic executive hire adds to Company's global leadership team and positions the Company for continued growth DURHAM, N.C.and BEIJING, July 13, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-
- 4y agoBRIBYBrii Biosciences Announces Commercial Launch of its Amubarvimab/Romlusevimab Combination Therapy for COVID-19 in ChinaPR NewswireThe Company is working closely with its commercial partners to supply the combination therapy to patients in need Brii Bio progressed the combination therapy from discovery to global Phase 3 data readout and first regulatory approval by the China N
- 4y agoBRIBYVIRBrii Biosciences Exercises Option for Vir Biotechnology's VIR-3434, a Broadly Neutralizing Monoclonal Antibody Targeting Hepatitis B in Greater ChinaPR NewswireExclusive development and commercialization rights to VIR-3434 in China strengthen Company's leadership and robust clinical pipeline in HBV Key partnership with Vir enables multitude of combination treatment options as part of Company's strategic appro